Frevecitinib - Kinaset Therapeutics/Vectura
Alternative Names: KN-002 - Kinaset Therapeutics/Vectura; VR-588Latest Information Update: 04 Feb 2025
At a glance
- Originator Vectura
- Developer Imperial College of Science, Technology and Medicine; Kinaset Therapeutics; Vectura
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors; TRPV1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma; Chronic obstructive pulmonary disease
- No development reported Inflammation
Most Recent Events
- 29 Jan 2025 The US FDA approves IND application for frevecitinib in Asthma
- 07 Sep 2024 Adverse event and pharmacokinetics data from phase I trial in Asthma and Chronic-obstructive-pulmonary-disease presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
- 04 Sep 2024 phase-I development in Asthma and Chronic-obstructive-pulmonary-disease is ongoing in United Kingdom (Inhalation, Powder) (NCT05006521)